Drug Profile
GAL 101
Alternative Names: GAL-101; MRZ-99030Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Tel Aviv University
- Developer Galimedix Therapeutics; Merz Pharmaceuticals GmbH
- Class Antiglaucomas; Dipeptides; Eye disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Protein aggregation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry age-related macular degeneration; Glaucoma
- Discontinued Alzheimer's disease
Most Recent Events
- 29 Mar 2023 Galimedix Therapeutics plans to develop GAL 101 for oral formulation for the treatment of Dry age-related macular degeneration and Glaucoma
- 29 Mar 2023 GAL 101 is still in Phase-I development for Glaucoma in Germany (Ophthalmic, Drops).
- 29 Mar 2023 Thea Open Innovation and Galimedix enter into License Agreement to develop and commercialise GAL 101 for Ophthalmic disorders in Europe, the Americas, the Middle East and Africa